Inhibitex's Hep C Drug Gets Fast-Tracked
Share
Follow Us
FDA grants fast track designation to Inhibitex HCV drug
PBR Staff Writer
Published 14 February 2011
The US Food and Drug Administration (FDA) has designated Inhibitex’s investigation of INX-08189, a potent guanosine nucleotide polymerase inhibitor for the treatment of chronic hepatitis C viral (HCV) infection, as a fast track development program.
Inhibitex is developing a series of proprietary nucleotide inhibitors that target the RNA-dependent RNA polymerase (NS5b) of HCV.
INX-189 is a protide of a 2′-C-methylguanosine analogue.
Inhibitex believes the preclinical and clinical studies of INX-189 completed to-date support its potential as a potent, once-daily, low dose oral therapy amenable to combination with other antivirals for the treatment of patients with all known genotypes of HCV.
Continue reading this entire article:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda-grants-fast-track-designation-to-inhibitex-hcv-drug-140211
